Rights and permissions
About this article
Cite this article
Allopurinol still best cost option in chronic gout. Pharmacoecon. Outcomes News 605, 2 (2010). https://doi.org/10.2165/00151234-201006050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006050-00002